Dr. Gauthier is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-288-6956- Is this information wrong?
Education & Training
Faculte Libre de Medecine de Lille, FranceClass of 2008
Certifications & Licensure
WA State Medical License 2014 - 2024
Clinical Trials
- A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Start of enrollment: 2022 Feb 21
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsTiming of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.Alexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, Salvatore Fiorenza, Jordan Gauthier, Jenna M Voutsinas, Qian Wu, Cecilia C S Yeung, Nicolas Gazeau, Barbara S Pe...> ;Blood Advances. 2024 Jan 23
- Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.Banerjee, R., Hirayama, A., Gauthier, J., Cassaday, R., Shadman, M., Cowan, A., Till, B., Green, D., Kiem, H., Gopal, A., Maloney, D., Banerjee, R., Poh, C.> ;Blood Advances. 2024 Feb 27
- Unveiling the autoreactome: Proteome-wide immunological fingerprints reveal the promise of plasma cell depleting therapy.Aaron Bodansky, David Jl Yu, Alysa Rallistan, Muge Kalaycioglu, Jim Boonyaratanakornkit, Damian J Green, Jordan Gauthier, Cameron J Turtle, Kelsey Zorn, Brian O'Donova...> ;Medrxiv. 2023 Dec 20
- Join now to see all
Abstracts/Posters
- Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant AbstractJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell TherapyJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical OutcomesJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA) Clinicians to Be Featured at the 2021 ASCO Annual MeetingJune 3rd, 2021- Seattle Cancer Care Alliance to Present New Research at 62nd Annual Meeting of the American Society of HematologyDecember 4th, 2020
Combination Therapy Boosts Durability of CAR T-cell Response in Hematologic CancersJanuary 10th, 2019- Join now to see all
Hospital Affiliations
Fred Hutchinson Cancer CenterSeattle, Washington
UW Medicine/University of Washington Medical CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
